SCHEDULE 13G/A: Vanguard Group Discloses 4.94% Passive Stake in AnaptysBio Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.94% beneficial ownership stake in AnaptysBio Inc. as of March 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 1,517,325 shares of AnaptysBio Inc. common stock.
• This represents 4.94% of AnaptysBio Inc.'s common stock outstanding.
• The filing is an Amendment No. 6 to a Schedule 13G, indicating a passive investment.
• Vanguard holds 0 shares with sole voting power, 23,140 shares with shared voting power, 1,475,166 shares with sole dispositive power, and 42,159 shares with shared dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a routine regulatory filing by a passive investor, providing no new positive or negative operational or financial information about the issuer. The stake is below 5%, indicating no intent to influence control.

Positives

• A major institutional investor like The Vanguard Group holds a significant, albeit passive, stake, which can be seen as a vote of confidence in AnaptysBio Inc.
• The filing confirms the passive nature of Vanguard's investment, indicating no intent to influence control.

Negatives

• The stake is below the 5% threshold, meaning Vanguard is not required to file a Schedule 13D, which would indicate an active intent to influence the company.
• The percentage of ownership (4.94%) is slightly lower than the 5% threshold, which might suggest a slight reduction or maintenance of a position just below the reporting requirement for active investors.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by a large asset manager, The Vanguard Group, regarding its passive investment in AnaptysBio Inc. It reflects standard portfolio management activities rather than a strategic industry move.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership by a passive institutional investor. It does not provide performance metrics for direct comparison to industry standards or specific comparable companies/projects.
• The 4.94% stake is a common size for passive index or fund holdings by large asset managers like Vanguard.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can offer some stability or confidence.

Key Dates

Keywords

AnaptysBio Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing